Molecular Docking of Phytochemical Compounds of Momordica charantia as Potential Inhibitors against SARS-CoV-2.
Infect Disord Drug Targets
; 22(3): e130122200221, 2022.
Article
in English
| MEDLINE | ID: covidwho-1892487
ABSTRACT
BACKGROUND:
Coronavirus disease 2019 (COVID-19) has been recently declared as a global public health emergency, where the infection is caused by SARS-CoV-2. Nowadays, there is no specific treatment to cure this infection. The main protease (Mpro) of SARS-CoV-2 and SARS spike glycoprotein- human ACE2 complex have been recognized as suitable targets for treatment, including COVID-19 vaccines.OBJECTIVE:
In our current study, we identified the potential of Momordica charantia as a prospective alternative and a choice in dietary food during a pandemic. MATERIALS ANDMETHODS:
A total of 16 bioactive compounds of Momordica charantia were screened for activity against 6LU7 and 6CS2 with AutoDockVina.RESULTS:
We found that momordicoside B showed the lowest binding energy compared to other compounds. In addition, kuguaglycoside A and cucurbitadienol showed better profiles for drug-like properties based on Lipinski's rule of five.CONCLUSION:
Our result indicates that these molecules can be further explored as promising candidates against SARS-CoV-2 or Momordica charantia can be used as one of the best food alternatives to be consumed during the pandemic.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Momordica charantia
/
COVID-19 Drug Treatment
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Infect Disord Drug Targets
Journal subject:
Communicable Diseases
/
Drug Therapy
Year:
2022
Document Type:
Article
Affiliation country:
1871526522666220113143358
Similar
MEDLINE
...
LILACS
LIS